Ischemic heart disease (IHD) is caused by the narrowing of arteries that work to provide blood, nutrients, and oxygen to the myocardial tissue. The worldwide epidemic of IHD urgently requires innovative treatments despite the significant advances in medical, interventional, and surgical therapies for this disease. Angiogenesis is a physiological and pathophysiological process that initiates vascular growth from pre-existing blood vessels in response to a lack of oxygen. This process occurs naturally over time and has encouraged researchers and clinicians to investigate the outcomes of accelerating or enhancing this angiogenic response as an alternative IHD therapy. Therapeutic angiogenesis has been shown to revascularize ischemic heart tissue, reduce the progression of tissue infarction, and evade the need for invasive surgical procedures or tissue/organ transplants. Several approaches, including the use of proteins, genes, stem/progenitor cells, and various combinations, have been employed to promote angiogenesis. While clinical trials for these approaches are ongoing, microvesicles and exosomes have recently been investigated as a cell-free approach to stimulate angiogenesis and may circumvent limitations of using viable cells. This review summarizes the approaches to accomplish therapeutic angiogenesis for IHD by highlighting the advances and challenges that addresses the applicability of a potential pro-angiogenic medicine.
Introduction
Angiogenesis is a fundamental process in both physiology and pathophysiology. It is an essential mechanism in fetal development, reproduction, wound healing, and cancer growth and metastasis. The formation and development of new blood vessels is also a potentially important remedy to pathologically impaired or absent blood flow to and from vital organs and tissues. A functional vascular system is essential for the proper maintenance of tissues and organs by delivering oxygen and nutrients, removing waste, and trafficking the transport of immune cells. The interruption of adequate blood flow can have devastating consequences.
Insufficient blood flow to the myocardium (coronary insufficiency or myocardial ischemia) is a major public health problem and a leading cause of death worldwide; ischemic heart disease (IHD) kills over 370,000 people annually in the USA [1] . The primary pathophysiological cause of IHD is atherosclerosis, a gradual blockage in blood flow causing poor oxygenation of the heart tissue that is coupled with endothelial dysfunction and age-related decline in angiogenic response [2] . Coronary atherosclerosis causes blockage of the coronary arteries, leading to myocardial ischemia, myocardial infarction (MI), and ischemic cardiomyopathy. Current medical interventions for IHD include pharmacologic therapy (antiplatelet drugs, β-blockers, or statins) for disease stabilization and reduction of acute events (e.g., myocardial infarction or sudden death) or immediate restoration of the blood supply via surgical treatment, such as coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI), two of the most common revascularization procedures performed worldwide [3, 4] . However, a significant number of patients are clinically refractory to medical therapy and are ineligible to receive either PCI or CABG due to the patient's clinical condition or to technological limitations of currently available therapies [2, 4, 5] . As a result, the development of advanced and targeted pro-angiogenic strategies for high-risk patients is urgently needed. The proposed methods to combat IHD include the delivery of protein(s), gene(s), cell(s) or, more recently, extracellular vesicles to induce vessel growth (Fig. 1) . In this review, we discuss the current approaches to revascularization therapy using therapeutic angiogenesis, the advances in research, the caveats, and the potential in clinical applications.
Concept of therapeutic angiogenesis
Fundamentally, angiogenesis is the formation of new vasculature from pre-existing vessels. Therapeutic angiogenesis involves exogenously administering an agent that stimulates the postnatal growth of new blood vessels to restore circulation to the tissue. Angiogenesis can be induced in several human and animal models of inflammation [6] , peripheral artery disease [7] , and ischemic heart disease [8] for vascular restoration. Due to the complex nature of this process, the induction of angiogenesis to revascularize ischemic tissue must be extensively coordinated and controlled to prevent critical adverse events, such as uncontrolled angiogenesis and leaky and immature vessel formation. Normally by adulthood, blood vessels are maintained in a state of quiescence but will deviate from this state, especially in coronary atherosclerosis, when there is a reduction of oxygen to the tissue. Under normal conditions, capillaries are stabilized by Bclassicf actors (Notch1, angiopoietins, and thrombospondin) that are balanced by pro-angiogenic cytokines such as vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), and platelet-derived growth factor (PDGF) within the circulation [9] . The angiogenic mechanism, in physiological and pathological states, can be broken down into three essential steps: (1) activation; (2) proliferation, migration, and sprouting of existing endothelial cells (ECs); and (3) vessel stabilization by pericytes. Angiogenic cytokines can bind directly to receptors or indirectly initiate the activation on the ECs, activating downstream signaling pathways to develop new capillary-sized blood vessels [10] . Homeostasis is then re-established through the influence of stabilizing signals from surrounding ECs, pericytes, and stromal cells. It should be mentioned that the importance of pro-angiogenic factors is more clearly understood when they are genetically knocked down, which reliably produces embryonic lethality [11] .
Vascular growth can be mediated by two additional processes: arteriogenesis and vasculogenesis. Arteriogenesis is the remodeling of collateral vessels to bypass a blockage to support distal portions of the limb or organ [12] . By producing larger vessels with an established tunica media, arteriogenesis can restore up to 30-40% of basal blood flow in critical stenosis, which is effective for tissue restoration and survival. However, this mechanism is reduced in activity due to aging and disease states [13] . Vasculogenesis is the de novo formation of vessels that establishes the primary vascular plexus. This is a hallmark mechanism that occurs when angioblasts accompanied by hematopoietic progenitor cells proliferate, migrate, and associate to form primitive vessels [14] . Although more prominently seen in early development, tissue ischemia can trigger postnatal vasculogenesis, which is mediated via the mobilization of endothelial progenitor cells (EPCs). These EPCs will then infiltrate the site of injury and can either differentiate into mature ECs or regulate pre-existing ECs via paracrine/juxtacrine signaling [15] , which makes EPCs a favorable candidate for therapeutic studies. Therefore, angiogenesis, arteriogenesis, and vasculogenesis are mechanisms that have been investigated as methods to stimulate therapeutic angiogenesis.
Protein/gene therapy
The use of proteins or genes to stimulate angiogenesis at the cellular level has been a well-established approach for researchers [16] . Protein therapy is performed by the intravenous, intra-arterial, intramuscular, or intramyocardial injection of a recombinant angiopeptide. The benefits of this method include a quantifiable biologic effect and the easy feasibility of reconstituting the purified protein in a buffer for an Boff-theshelf^treatment. To date, several agents can be administered to promote vascular growth. Among these factors, VEGF is the most important for the development and differentiation of the vascular network, with favorable preclinical evidence showing significantly increased perfusion, improved tissue metabolism, improved cardiac function, and cardiac protection [17] . However, the promising potential of such growth factors has not yielded much clinical success. The principal limitation of proteins is the short half-life of exogenous proteins in target tissue, which reduces the therapeutic benefit. Therefore, this method could be improved by the sustained expression of the angiopeptide.
In hopes of prolonging the effects of angiogenic cytokines, much attention has been directed to the stimulation of the major genetic regulators of angiogenesis. To do this, administration of a nonviral or viral vector delivery system allows for the consistent replication of the gene responsible for the angiopeptide. The most widely accepted nonviral system includes recombinant plasmid DNA, which suffers from low transfection efficiency, leading to minimal therapeutic benefits. Therefore, empty viral vectors, including adeno-, adeno-associated, and retroviruses, which can transduce postmitotic cells for long-lasting protein expression, represent a major advance in this field of research. Clinical trial evidence for the transfection efficacy of empty viral vectors was found in the Kuopio Angiogenesis Trial, which studied the intramyocardial injection of Ad-VEGF 165 versus plasmid DNA-VEGF 165 during percutaneous coronary angioplasty. The administration of Ad-VEGF 165 allowed a higher degree of myocardial perfusion [18] . Recently, adenoassociated viral vectors encoding human VEGF-transduced pectineus muscular flaps increased the formation of new tissue through the induction of angiogenesis, which can be used as a strategy for heart tissue regeneration [19] . However, the use of viral vectors as a delivery method of angiopeptides also presents a risk of immune attack and still needs to be further optimized for dose, delivery routes, and administration. Clinical trials, such as the Randomized Evaluation of VEGF for Angiogenesis (REVASC) trial [20] , Ripa et al. [21] , and the Angiogenic Gene Therapy (AGENT) trial [22] , produced minimal results, which may be because virtually all clinical trials have been carried out as monotherapy and could be improved with combinatorial therapy.
Combination methods employing the concurrent use of two or more proteins, genes, or a combination of both protein and genes have been studied to serve as a more effective yet stable way to promote vascular growth. VEGF has had highly debatable success for therapeutic angiogenesis; therefore, Bouïs D et al. decided to use a combination plasmid encoding both VEGF and PDGF and revealed that it had inducing effects on endothelial migration and tube formation [23] . Additionally, implementing this paired approach, researchers observed that simultaneous delivery of FGF-2 and PDGF-β significantly improved the formation of collateral networks and blood perfusion in rat and rabbit ischemic hind limb models [24] . Combinations of VEGF and FGF [25] , HGF and placental-derived growth factor (PlGF) [26] , and bone morphogenetic proteins-2 with FGF-2/VEGF [27] as well as many others have provided convincing preclinical evidence for vascular growth and warrant future studies in clinical trials (Table 1) . Future directions may [18, 20] Randomized Evaluation of VEGF for Angiogenesis (REVASC): Exercise time to 1 mm ST-depression differed significantly at week 26 compared to control AAV-VEGF Enhanced tissue formation and significantly increased number of arterioles [19] Plasmid VEGF Mobilization of progenitor cells from bone marrow were seen once G-CSF was administered in conjunction to plasmid VEGF165 [21] Ad-FGF4 Angiogenic Gene Therapy (AGENT): Ad-FGF4 was administered and had an acceptable safety profile with a trend toward anti-ischemic effect [22] Plasmid VEGF + PDGF Induced endothelial cell migration and tube formation [23] FGF-2 + PDGF-ββ Stimulated collateral arteriogenesis, significant increase in vascularization and improvement in blood flow [24] VEGF-A + FGF-2 Stimulates cell recruitment and formation of functional neovasculature in vivo [25] HGF + PlGF Induced angiogenesis [26] BMP-2 + FGF + VEGF Promoted angiogenesis with lower concentrations needed of each factor [27] include testing the efficacy and finding the optimal dosage of these growth factors in combination, which may lead to more clinically relevant outcomes.
Stem/progenitor cell therapy
In the last decade, stem cell transplantation to induce angiogenesis to repair the ischemic myocardium has emerged as an innovative alternative to traditional methods of gene or protein stimulation. This technique transplants viable cells into the myocardium to provide a regulated source of secreted growth factors and cytokines beneficial to the overall goal of reducing the amount of cardiomyocyte loss and improving the heart's vascular network. Stem and progenitor cells possess beneficial qualities such as self-renewal, high differentiation capacity, colocalization with vessel components, and proliferation capability, making them ideal inducers or components of vascular growth. Stem and progenitor cells derived from various cell populations have shown therapeutic benefit in boosting angiogenesis as well as restoring ischemic heart tissue function. [28, 29] . Furthermore, BM-derived stem cells have been pushed into early-phase clinical trials [30] . A pilot study of cell-based therapies was introduced by Asahara et al., who observed that EPCs, isolated from human peripheral blood, contributed to vessel growth in ischemic tissues. This angiogenic potential has been replicated in clinical studies using cardiac progenitor cells [31, 32] and ASCs [33] . However, excitement about EPCs and their phenotype, origin, and mechanism has been dampened because of unresolved questions, despite results demonstrating improved neovascularization in animal models of ischemia [34] . It is widely accepted that current EPC nomenclature describes two distinct subpopulations: endothelial colony forming cells and myeloid angiogenic cells [35] . Thus, the specific phenotype, mechanism, and biological function provides a clear indication of the way they accomplish angiogenesis. Currently, there are several phase III/IV clinical trials using a variety of different cell types that display the clinically relevant outcomes using cytotherapy based on the improvement of cardiac function (Table 2) . Adult BM cells were examined by meta-analysis from patients who suffered from IHD and this systematic review concluded that these cells had positive and considerable therapeutic benefits [44] . In a randomized study, BM-MSCs cells were tested for safety in patients who have had an acute myocardial infarction. The study revealed that there was no treatment-related toxicity during the intracoronary administration of the cells [45] . Similarly, intramyocardial injection of autologous BMMNCs was evaluated for the long-term effect of this treatment plan. The results from that study, which were similar to others [36] , indicated that intramyocardial transplantation was safe and improved survival and clinical symptoms with chronic ischemic disease [37] . The intracoronary administration of BM-derived cells at 4 months showed significant improvement in left ventricular ejection fraction and after 1 year was associated with a reduction in myocardial infarction and clinical endpoint of death [38] . The CD133+ BM-derived cell population has been of interest due to their clinical involvement in restoring myocardial tissue viability and induction of angiogenesis [39] . Results from the Cardio133 trial, intramyocardial transplantation of CD133+ BM-derived stem cells in patients with chronic ischemic heart disease showed minimal improvements in scar size and regional perfusion [40] . CD34+ cells have also been investigated for their therapeutic benefits for IHD. In a phase III, randomized, doubleblinded study called the RENEW study, intramyocardial injection of CD34+ cells improved angina frequency and exercise tolerance [41] . Moreover, EPC-capturing stents have also been utilized to counter the angiographic outcomes in percutaneous coronary intervention. The number of circulating EPCs was increased by twofold [42] . Along with the success, there are still some caveats that overwhelm this type of therapeutic angiogenesis, which includes the development of robust approaches for cell characterization, uniform isolation and/or maintenance, survival, prevention of microembolism, and optimal delivery strategies. It is estimated that 40-75% of injected cells will succumb to cell death within the first three days [43] , especially in cases where multiple cell types will be replaced and restored because long-term functional integration remains a challenge for effective clinical improvement [46] . Currently, noninvasive ultrasound-targeted microbubble destruction technology aims to improve the efficacy of transplanted cells [47] . Additionally, cell sheets-an attached mono-or multilayer xenon-free graft that is made of viable cells with their appropriate extracellular matrix-may also circumvent poor survival of cells for therapeutic interventions [48] . The use of iPSC-derived cells, although not currently used in clinical trials for the treatment of IHD, has shown positive preclinical evidence. These fully reprogrammed adult cells can be differentiated to a bona fide cell type, typically by a differentiation cocktail expressing factors for the specialized cell type. Moreover, iPSC-derived cells have been shown to rescue tissues from ischemia by the induction of angiogenesis [49] . The oncogenic cocktail of transcription factors continues to invite much controversy. The epigenetic memory of iPSCderived cells makes them high-risk for tumorigenic activity and is often a testable measure that occurs when demonstrating the regenerative ability of these cells. Alternatively, induced vascular progenitor cells (iVPCs), which are partially reprogrammed vascular ECs, have been proposed to counter iPSC usage. IVPCs have been shown to enhance coronary collateral flow in a repetitive ischemia rat model and do not present a risk of tumorigenesis, which was confirmed in a 47-day tissue harvest study of injected iVPCs and iPSCs [50] . These cells present higher promise for vascular tissue engineering using cell-based approaches for cardiac regeneration and ischemic rescue. In conclusion, optimizing cell sources is a critical factor for the clinical success of this approach.
Combinational protein/gene and stem/progenitor cell therapy
The combinational method using proteins, genes, and cells has been investigated to enhance the effects observed with monotherapy strategies. The coinjection of BM-MSCs with adenoassociated viral vector of VEGF into the ischemic myocardium was shown to increase the cardiac function and survival of transplanted cells [51] . Moreover, MSCs transfected with adenoviral vector encoding hypoxia inducible factor-α (HIF-1α) and co-transplantation of MSCs and adenoviral vector expressing HIF-1α were both studied after intramyocardial injection in a rat myocardial infarction model and showed Increased number and mobilization of circulating EPCs and lower restenosis rate NCT00494247 [43] significantly improved cardiac function in the peri-infarcted region [52] . The use of this technique has encouraged researchers to investigate dual therapy to further enhance results for cardiac regeneration and improvement post ischemic attack. Before transplantation into IHD patients, interventional cells can be exposed to hypoxia to mimic the ischemic environment in the host which causes the upregulation of proangiogenic and pro-survival factors and therefore equips the cells to be resistant to cell death under the deprived conditions. Additionally, the dual use of stem cells and proteins has had clinical success. Duan et al. showed that treatment of myocardial ischemia with BM-MSCs overexpressing hepatocyte growth factor increased capillary density and reduced the area of ischemia [53] . Moreover, the combination of cardiovascular disease pharmaceutics with additional growth factors has also been recognized as an alternative strategy for cardiovascular improvement. Statin and stromal cell-derived factor-1 additively promoted angiogenesis by enhancing progenitor cell mobilization and incorporation into new vessels in ischemic hindlimb mouse models [54] . 
Microvesicle/exosome therapy
Studies have proposed that the beneficial properties of transplanted stem cells are mainly carried out by paracrine effects rather than cell differentiation. Therefore, many researchers are interested in the secreted factors released from transplanted cells [56] . In addition to growth factors and chemokines, the exploratory field of extracellular vesicles (EVs) is quickly gaining much attention as a therapeutic strategy for pro-angiogenic treatment. EVs are widely used to refer to the heterogeneous classes of small membrane-enclosed vesicles, which include exosomes, microvesicles, ectosomes, budding vesicles, shedding vesicles, and apoptotic bodies [57] . These vesicles are released from the surface of different cell types and can be isolated from bodily fluids such as milk, sweat, semen, and urine [58] . Exosomes are doublemembraned nanovesicles that range 30-100 nm in diameter that can transfer lipids, proteins, mRNA, and microRNAs that have regulatory effects on the genetic and epigenetic processes in recipient cells [59] [60] [61] . Microvesicles (MVs) originate from the budding of the plasma membrane and are characteristically larger than exosomes [62, 63] . For this review, discussion will be limited to exosomes and MVs, and it will be specific regarding the nomenclature and function mentioned in the cited literature. The intracellular exchange of exosomes has been shown to stimulate pro-angiogenic, proliferative, anti-apoptotic, and anti-inflammatory signaling cascades in cardiovascular disease [64] . MicroRNAs retain strong stability and express tissue-specific patterns and are enriched in exosomes to induce cardiac repair and the reduction of fibrosis in ischemic myocardium models [65] . Our research has also reported that the transfer of miRNA-31 encapsulated in MVs from human ASCs promotes vascular EC tube formation and migration which are indicative of an angiogenic response [66] . Moreover, cells that participate in cardiac tissue repair are of interest as cell source candidates to isolate extracellular vesicles from. Epicardial epithelial to mesenchymal transition (EMT) is a key step in heart development that occurs at a higher rate following myocardial infarction. In a study by Foglio et al., exosomes released into the pericardial fluid by epicardial cells induced epicardial EMT arteriogenesis and reduced cardiomyocyte apoptosis [67] . Using a proteomic approach, they were able to identify clusterin, a heterodimeric secreted glycoprotein of 75 kDa, as a key component encapsulated within pericardial fluid exosomes. Similarly, exosomes isolated from human pericardial fluid have also been shown to be enriched with cardiovascular-expressed microRNAs and promote vessel formation [68] . Thus, the exchange of protein and microRNAs within exosomes has been a method to explore the mechanistic approach that occurs once exosomes are internalized into recipient cells [69] . Overall, exosomes from MSCs [70] [71] [72] [73] [74] [75] , cardiac progenitor cells [76] [77] [78] [79] [80] , embryonic stem cells [81, 82] , and human pericardial fluid [67] have all been shown to improve cardiac function by increasing capillary density, among other factors (Table 3) . Cell-derived exosomes also evade limitations of using cell-based therapies, home to specific tissue, and serve as a novel drug delivery mechanism, with their bilipid membranes aiding in the protection of biologically active cargo allowing a longer half-life in patients [83] .
Scientists have recognized exosomes as natural nanocarriers for use as advanced drug delivery systems. Recently, hybrid exosomes have been engineered by fusing their membranes with liposomes. Liposomes are vesicles with a simple lipid bilayer typically conjugated to polyethylene glycol to aid in immune invasion. The change in lipid composition with the concurrent properties already contained within the exosomes had increased cellular uptake of exosomes [84] . One of the most widely accepted approaches for therapeutic agent loading involves transfecting exosome-producing cells to overexpress angiogenic genes [85] . Direct loading of isolated exosomes by incubating them with the genetic material of interest has also been reported [86] . Additionally, transfecting cells with an expression construct encoding a fusion protein containing the ligand of interest attached to an endogenous exosome membrane protein, such as MFGE8 and LAMP2B, has also been used to aid in exosome targeting [87, 88] . Furthermore, pretreatment of cells with activators to augment cell recruitment and survival in the ischemic target area and/or the improvement of cell functions, such as their paracrine ability to release proangiogenic factors and vasoactive molecules, has also been rigorously investigated. By ischemic preconditioning of donor cells, it has been shown to be a powerful approach to enhance cell survival [89] and regeneration of stem cells [90] . Several studies have shown an increased release of EVs in response to hypoxia as well as acidosis and oxidative stress [91] . Moreover, one study found that when glioblastoma multiforme cells were grown in hypoxic compared to normoxic environments, these vesicles were potent inducers of angiogenesis ex vivo and in vitro [92] . Cell-preconditioning has an additive effect by promoting survival factors and inducing angiogenesis, which may prove beneficial for IHD.
Mechanistic studies still warrant further investigation, and functional studies of EVs in human biological fluids are still lacking. Such studies are important to characterize the relevance of exosome-based communication in human pathophysiology. Standardization of exosome and microvesicle isolation techniques is required to establish retention of the pure vesicles desired; to date, there are various isolation methods that complicate using this therapy [93] . Additionally, due to its novelty within the literature, this approach has not been moved to clinical trials as a pro-angiogenic. However, clinical trials using exosome administration in humans have been tested for cancer immunotherapy, the safety of the treatment has been established [94] , and there are several completed registered NIH clinical trials using exosomes as diagnostic agents [95] .
Engineered exosome therapy
Another critical finding in the field has shown that cells senesce with age, resulting in a decline of their ability to release exosomes [96] . To ensure stable production of exosomes, synthesizing artificial vesicles is a way to bypass this caveat. Synthetic exosomes can be prepared from amphiphilic linear block copolymers. There are several methods to produce these vesicles, including solvent exchange, film rehydration, electroformation, and double emulsion methods. Artificial exosomes covalently attach with HSP70 peptides and could inhibit the death of cardiomyocytes induced by hypoxia [97] . Engineered exosomes with antibodies, peptides, or carbohydrates have been used to aid in the targeting of specific tissues or cells. This method could decrease the minimum concentration of artificial exosome dose and reduce adverse effects. Moreover, [81] synthetic exosomes or nanoparticles have emerged as a groundbreaking development for fast diagnosis, molecule delivery, and tissue engineering. Nanoparticles range in diameter from 1 to 100 nm and are artificial replicas of the exosomal phenotype. Nanoparticles can be directly loaded to contain pro-angiogenic peptides or can be used as nonviral gene vectors to establish genetically engineered stem cells for in vivo cardiac repair [98] . Nanoparticles can be synthesized by two general approaches: top-down or bottom-up. Top-down approaches typically involve imposing a structure on a flat surface and adding or removing thin layers of materials. The bottom-up approach uses molecular chemistry to form nanostructures. Overall, size plays an important role and can be advantageous to medicine, as nanoparticles can cross the blood-brain barrier. However, nanoparticles are still subjected to immunosurveillance, which can lead to their degradation or clearance from the bloodstream. In conclusion, engineered exosomes could be a promising method to induce therapeutic angiogenesis and allow for mass production without the need for immortalized cells.
Summary and conclusion
Overall, protein, gene, cell, and exosome/microvesicle therapies have all contributed to the forward progress of proangiogenic treatment moving further down the pipeline to cardiovascular therapeutics. The vehicle that will stimulate the therapeutic angiogenic effect is of major importance to this field. Initially, protein and gene therapy approaches were implemented due to their vast foundational knowledge and the ease of being able to pharmaceutically insert these factors into medicinal constructs, whereupon administration allows for relatively easy testing to see if there is any clinical value. However, the results observed in preclinical studies are not the same as those seen in phase III clinical studies [99] . In that regard, gene/protein therapy is still being observed as a potentially wise choice and is feasible for off-the-shelf availability. The use of stem/progenitor cells from various sources is attractive due to isolation efficiency and in vivo success. However, there is a need to investigate the optimal cell source and regulation techniques to ensure cell viability, differentiation, localization to target sites, and a decreased risk of tumorigenesis. The use of multiple proteins/genes or proteins/genes with concurrent use of stem/progenitor cells are useful alternatives to monotherapy. In this way, it targets two hurdles: (1) efficacy in integration into host vessels and (2) aiding in cell survival and transplantation, thus emulating a more comprehensive therapeutic angiogenesis model. Moreover, the use of exosomes/microvesicles, the most recent of the three approaches, is a very striking method relative to conventional methods. These small microparticles have the advantage of their size and contain a content that can elicit a response from the target cells. This method evades the limitations of the other approaches but must be studied vigorously before clinical trials are initiated.
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